Wise Therapeutics (Wise), a developer of game-based digital therapeutics, announces the results of a study conducted in collaboration with NYU Langone Health, published in Frontiers in Neurology.
This clinical trial demonstrates how Wise’s gamified therapies can serve as an at-home, non-pharmaceutical treatment for anxiety in multiple sclerosis (MS) populations. Topline results suggest that Wise’s app-based approach to gamified attention bias modification training (ABMT) reduced self-reported anxiety by 38.3% in adults and 20.1% in youth. Additionally, broad negative mood, as measured by the Positive and Negative Affect Schedule (PANAS), was reduced by 14.5%, a media release from Wise Therapeutics Inc explains.
“Like many of our proof of concept trials, this study used our lead wellness product Personal Zen to demonstrate the potential clinical impact of our ABMT products. Leveraging data from these studies, as well as real world deployments of Personal Zen, we are now developing new ABMT therapies with adaptive gameplay features that personalize the experience to the attentional habits of individual patients.”
— Dr. Tracy Dennis-Tiwary, Co-Founder and Chief Science Officer of Wise Therapeutics
“Our intention is to market our next generation of products as Prescription Digital Therapeutics (PDTs) for targeted populations like MS, taking advantage of new regulatory and reimbursement pathways that have emerged to help meet the heightened need for accessible mental health treatments.”
— Raj Amin, Chief Executive Officer of Wise Therapeutics
[Source(s): Wise Therapeutics Ltd, PR Newswire]
Related Content:
Kessler Investigates MS-Related Social Cognition Link with Mood and Fatigue
Pack Health Partners with National Multiple Sclerosis Society to Support Patients with MS
Childhood Trauma Has This Effect on Multiple Sclerosis
